Manufacturing Process of (αS)-α-Methyl-3,5-Bis(Trifluoromethyl)Benzenemethanol under GMP

• GMP-compliant synthesis route starting from 3,5-bis(trifluoromethyl)benzaldehyde via asymmetric reduction to achieve high enantiomeric excess.
• Industrial purity ≥99.0% with rigorous in-process controls, full COA documentation, and chiral HPLC validation.
• Bulk pricing and scalable supply available directly from NINGBO INNO PHARMCHEM CO.,LTD.—a premier global manufacturer of this key pharmaceutical intermediate.

The demand for enantiomerically pure intermediates like (1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethanol (CAS: 225920-05-8)—also known as (αS)-α-Methyl-3,5-bis(trifluoromethyl)benzenemethanol—has surged due to its critical role in synthesizing high-value active pharmaceutical ingredients (APIs). As a chiral benzylic alcohol bearing two electron-withdrawing trifluoromethyl groups, it serves as a strategic building block in CNS modulators, kinase inhibitors, and anti-inflammatory agents. Ensuring consistent industrial purity and stereochemical integrity requires a tightly controlled manufacturing process aligned with ICH Q7 and cGMP guidelines.

GMP-Compliant Production Workflow from Raw Materials to Final Product

The industrial-scale synthesis of (1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethanol begins with commercially available 3,5-bis(trifluoromethyl)benzaldehyde—a compound accessible via Friedel-Crafts acylation or halogen-metal exchange routes, as referenced in Org. Synth. protocols. The core transformation is an enantioselective reduction of the aldehyde to the corresponding (S)-alcohol.

NINGBO INNO PHARMCHEM CO.,LTD. employs a catalytic asymmetric transfer hydrogenation (ATH) using chiral Ru- or Rh-based catalysts (e.g., TsDPEN derivatives) in isopropanol/water mixtures at 40–60°C. This method avoids cryogenic conditions and hazardous reductants (e.g., DIBAL-H), enhancing safety and scalability. Typical reaction parameters include:

• Catalyst loading: 0.5–1.0 mol%
• Substrate concentration: 15–25 wt% in solvent
• Reaction time: 6–12 hours
• Conversion: >99.5% (by GC)
• Enantiomeric excess (e.e.): ≥99.0% (by chiral HPLC)

When sourcing high-purity (1S)-1-[3,5-Bis(trifluoromethyl)phenyl]ethanol, buyers should prioritize suppliers with validated chiral control and full traceability from raw material to final drum.

Downstream Processing & Isolation

Post-reaction, the mixture undergoes:

1. Quenching and phase separation: Dilution with water followed by extraction into ethyl acetate or MTBE.
2. Washing sequence: Aqueous NaHCO₃ (to remove acidic impurities), brine (to reduce emulsion), and deionized water.
3. Drying and concentration: Anhydrous Na₂SO₄ drying, followed by rotary evaporation under reduced pressure (≤50°C bath).
4. Crystallization or distillation: For GMP batches, crystallization from hexane/IPA is preferred to isolate the product as a white to off-white solid (mp: 68–72°C).

Chiral Control Strategies During Synthesis

Maintaining stereochemical fidelity is non-negotiable. NINGBO INNO PHARMCHEM CO.,LTD. implements a multi-tiered chiral assurance system:

• In-process chiral HPLC monitoring at 25%, 50%, 75%, and 100% conversion to detect racemization or epimerization early.
• Catalyst batch qualification: Each ligand/metal precursor lot is pre-screened for enantioselectivity in a miniaturized reaction.
• Strict oxygen/moisture exclusion: Reactions conducted under N₂ with <10 ppm H₂O in solvents to prevent catalyst deactivation.

This robust approach ensures that the final synthesis route delivers consistent e.e. ≥99.0%, meeting stringent regulatory expectations for chiral drug intermediates.

Quality Assurance Protocols and In-Process Testing

All batches are manufactured in ISO 9001-certified and FDA-inspected facilities, with comprehensive documentation per ICH Q7. Key quality attributes include:

Parameter	Specification	Test Method
Assay (GC area %)	≥99.0%	GC-FID, DB-5 column
Enantiomeric Excess	≥99.0%	Chiral HPLC (Chiralpak AD-H)
Residual Solvents	Meets ICH Q3C Class 2 limits	GC-Headspace
Water Content	≤0.5%	Karl Fischer
Heavy Metals	≤10 ppm	ICP-MS

Each shipment includes a full COA (Certificate of Analysis) with spectral data (¹H NMR, ¹⁹F NMR, IR), chromatograms, and GMP statement. This level of transparency supports seamless regulatory filings in EU, US, and APAC markets.

Bulk Supply and Commercial Advantages

As a leading global manufacturer, NINGBO INNO PHARMCHEM CO.,LTD. offers this intermediate in quantities ranging from kilograms to multi-ton scales, with competitive bulk price structures based on volume and purity tier. The company’s vertically integrated production—from benzaldehyde to final chiral alcohol—ensures supply chain resilience and cost efficiency unmatched in the industry.

For pharmaceutical developers requiring a reliable source of high-purity (1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethanol, partnering with NINGBO INNO PHARMCHEM CO.,LTD. guarantees technical excellence, regulatory compliance, and scalable logistics worldwide.